Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies
Not available.
Saved in:
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Ferrata Storti Foundation
2025-01-01
|
Series: | Haematologica |
Online Access: | https://haematologica.org/article/view/11927 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832577697788723200 |
---|---|
author | Pierre Peterlin Maxime Jullien |
author_facet | Pierre Peterlin Maxime Jullien |
author_sort | Pierre Peterlin |
collection | DOAJ |
description |
Not available.
|
format | Article |
id | doaj-art-c1146753b87c43159a4cff95830c4cb6 |
institution | Kabale University |
issn | 0390-6078 1592-8721 |
language | English |
publishDate | 2025-01-01 |
publisher | Ferrata Storti Foundation |
record_format | Article |
series | Haematologica |
spelling | doaj-art-c1146753b87c43159a4cff95830c4cb62025-01-30T19:44:19ZengFerrata Storti FoundationHaematologica0390-60781592-87212025-01-01999110.3324/haematol.2025.287378Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des MyélodysplasiesPierre Peterlin0Maxime Jullien1Clinical Hematology, Nantes University Hospital, NantesClinical Hematology, Nantes University Hospital, Nantes Not available. https://haematologica.org/article/view/11927 |
spellingShingle | Pierre Peterlin Maxime Jullien Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies Haematologica |
title | Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies |
title_full | Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies |
title_fullStr | Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies |
title_full_unstemmed | Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies |
title_short | Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies |
title_sort | response to comment on flt3 ligand kinetic profile predicts response to treatment in patients with high risk myelodysplastic syndrome chronic myelomonocytic leukemia receiving cpx 351 a study from the groupe francophone des myelodysplasies |
url | https://haematologica.org/article/view/11927 |
work_keys_str_mv | AT pierrepeterlin responsetocommentonflt3ligandkineticprofilepredictsresponsetotreatmentinpatientswithhighriskmyelodysplasticsyndromechronicmyelomonocyticleukemiareceivingcpx351astudyfromthegroupefrancophonedesmyelodysplasies AT maximejullien responsetocommentonflt3ligandkineticprofilepredictsresponsetotreatmentinpatientswithhighriskmyelodysplasticsyndromechronicmyelomonocyticleukemiareceivingcpx351astudyfromthegroupefrancophonedesmyelodysplasies |